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ABSTRACT
Fragile X-associated tremor/ataxia syndrome (FXTAS) is an X-linked late-onset
neurodegenerative disorder caused by a noncoding trinucleotide repeat expansion in the FMR1
gene. This gene produces fragile x mental retardation protein (FMRP), an RNA binding protein
whose targets are involved in brain development and synaptic plasticity. One of the proposed
mechanisms of FXTAS pathogenesis is an RNA gain-of-function in which the repeat expansion
causes toxic mRNA that sequesters important proteins in the cell, interfering with their functions.
Another suggested method of pathogenesis is through a mutant protein called FMRpolyG. This
protein results from repeat-associated non-AUG (RAN) translation, in which the expanded
repeats are translated where they otherwise would not be. This protein co-localizes with
intranuclear inclusions and nuclear membrane proteins, causing disorganization of the nuclear
lamina in FXTAS patient brain samples and neurons differentiated from FXTAS patient-derived
induced pluripotent stem cells (iPSCs). iPSC technology involves reprogramming an adult
somatic cell back to an embryonic-like state, allowing it to be differentiated into all cell types. A
limit with iPSCs, though, is modeling late-onset disorders because the cells lose all age-related
features during reprogramming. Progerin, a truncated form of the lamin A protein, has been used
to age neurons differentiated from Parkinson Disease (PD) patient-derived iPSCs. Progerinmediated aging was found to unmask PD-like phenotypes in those neurons, making it a
promising technology for modeling late-onset disorders such as FXTAS. In this study, we
investigated the link between the aging process and FXTAS pathogenesis in neurons
differentiated from FXTAS patient-derived iPSCs with the use of progerin. Progerin transduction
was successful in aging the FXTAS neurons. The presence of FMRpolyG was confirmed and an
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interaction with Lap2 was observed. In some neurons, there was also an observed interaction
between FMRpolyG and progerin. Overall, this data suggests that there is an interaction between
the mutant FMRpolyG protein and the nuclear membrane during aging, which may contribute to
the cell death that causes neurodegeneration in FXTAS patients.
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CHAPTER I: INTRODUCTION
The fragile X mental retardation 1 (FMR1) gene is located on the long arm of the Xchromosome (Xq23.3) and is responsible for producing FMR protein (FMRP)1. The FMR1 gene
carries a CGG trinucleotide repeat in the 5’ untranslated region (UTR)1-8. In the normal
population, the repeat size ranges from 5 to 40 and is most commonly found around 301.
Expansion mutations of this CGG repeat may lead to different disorders. Fragile X Syndrome
(FXS), one of the leading genetic causes of intellectual disability, results from an expansion to
over 200 CGG repeats, classified as a full mutation2,6,8. A repeat expansion between 55 and 200
is classified as a premutation and puts carriers at risk for fragile x-associated primary ovarian
insufficiency (FXPOI) and fragile X-associated tremor/ataxia syndrome (FXTAS)1. Currently,
the only treatments for these disorders are aimed at controlling symptoms, with no diseasemodifying treatments available at this time.
The FMR1 gene has 17 exons, with a messenger RNA (mRNA) transcript of about 3.9
kilobases (kb)9. The FMR1 transcript undergoes alternative splicing, which results in six
isoforms of FMRP throughout different body tissues9. Although FMRP is found throughout the
body, the brain is one of the organs with the highest amount. The protein is present not only in
the cell bodies of neurons but in the dendrites and synaptic clefts as well9,10. FMRP has RNA
binding domains and it is estimated to bind with ~4% of mRNAs in the brain, whose functions
include neuronal development and regulation of synaptic plasticity10. It has been shown in
sedimentation assays that FMRP co-localizes with active polyribosomes, the machinery
responsible for the translation of mRNA into protein, which indicates a role in mRNA
metabolism9,10. Deletion of FMRP results in upregulation of expression of FMRP binding
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partners, suggesting that FMRP has an inhibitory role in mRNA processing9,10. Furthermore,
FMRP has both a nuclear localization signal and a nuclear export signal, which indicates a
potential function of shuttling mRNA from the nucleus to the cytoplasm9,10.
FXS is a neurodevelopmental disorder that results from complete silencing of FMR111.
The large expansion to over 200 CGG causes the gene to become hypermethylated, turning off
the promoter, which in turn stops transcription of FMR1 mRNA11. While the full mutation can
affect both males and females, it affects males to a higher degree due to X-inactivation in
females11. This occurs because females have two X-chromosomes, whereas males have one X
and one Y-chromosome. Cells only need the genetic information from one X-chromosome, so in
females, one of the two is randomly inactivated in each cell during early embryonic
development, which is then conserved through subsequent cell divisions12. The inactivated
chromosome is permanently packaged in a way that prevents gene transcription12. Because the
selection of which X-chromosome is inactivated is random, some cells will inactivate the Xchromosome with the FMR1 mutation, attenuating its deleterious effects. Conversely, males only
have one X-chromosome, so all cells will contain the mutant FMR1 gene, resulting in a more
severe disorder than is seen in females. Clinical features of FXS may include large ears, an
elongated face, hypotonia, and hyperflexible joints (figure 1)11,13,14. Symptomatic presentation
may range from mild to severe intellectual disability, autistic-like behavior, mood disorders,
hyperactivity, and fine motor and learning deficits11,13. The prevalence of FXS is about 1 in
4,000 males and 1 in 7,000 females6.
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Figure 1. Common physical features of Fragile X Syndrome. These features can include large ears and an
elongated face. Adapted from14.

The CGG tract of the FMR1 gene is unstable, which can result in intergenerational
expansion from the normal range of 5-40 to between 55 and 200 during gametogenesis15. This
range is classified as the premutation, which can subsequently expand to greater repeat lengths
within the premutation range or to the full mutation (over 200 repeats) in future generations15.
The premutation range is associated with lower penetrance disorders distinct from FXS.
Fragile X-associated tremor/ataxia syndrome is a late onset neurodegenerative disorder
caused by the premutation expansion of the CGG tract. Symptoms of FXTAS include cerebellar
ataxic gait, intention tremor, Parkinsonism, decline in cognitive function, and peripheral
neuropathy6. While approximately 1 in 130-250 females and 1 in 250-810 males carry the FMR1
premutation, only about 16% of female and around 40% of male carriers will develop FXTAS in
their lifetime6,13. Individuals with premutation repeat lengths above 70 are at greater risk for
developing FXTAS, and severity is correlated with increasing repeat length16. Symptom onset
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generally begins around the age of 50, but increasing repeat length and age of onset are inversely
correlated16.
FXTAS neuropathology may present with atrophy throughout the cerebrum and
cerebellum1,6. Loss of Purkinje cells and astrocytosis predominantly in the subcortical cerebral
white matter are observed1. Ubiquitin-positive intranuclear inclusions are observed in neurons
and astrocytes throughout the brain and brainstem and are prominent in the hippocampus1.
Interestingly, these inclusions are rarely present in Purkinje cells despite their observed drop out,
which may indicate that the inclusions are not necessary for cellular degeneration and may even
play a protective role1. One predominant neuropathological feature of FXTAS is an MCP sign,
where the middle cerebral peduncle atrophies. The middle cerebral peduncle is the connection
point from the body to the cerebellum and is useful in planning and refining movement and
motor function17.
Compared to normal individuals, carriers of the FMR1 premutation have about a 5 to 10fold increase in FMR1 mRNA levels, in contrast to FXS where mRNA is virtually absent1.
Counterintuitively, although mRNA levels are increased in FXTAS, levels of FMRP are normal
or reduced. It is also important to note that individuals with FXS do not develop the
neurodegeneration seen in FXTAS. From this, it is hypothesized a potential mechanism of
FXTAS pathology is RNA gain-of-function. Expanded FMR1 mRNAs form folded hairpins that
cause accumulation and intranuclear inclusions that sequester RNA-binding proteins essential for
cell viability1. One of particular importance is DiGeorge syndrome critical region 8 (DGCR8),
which binds preferentially to the repeat expansion1,5. This protein is a binding partner to
DROSHA, a double-stranded RNA-specific endonuclease that is involved in the processing of
primary microRNA (miRNA) to precursor miRNA1,5. Further cleavage of precursor miRNA by
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the endonuclease DICER produces mature miRNA that is then able to perform
posttranscriptional gene suppression5. This posttranscriptional regulation is crucial for the
growth and survival of neurons, which suggests that sequestration of regulatory proteins may
cause FXTAS-related cellular dysfunction and death5. Other RNA binding/processing proteins,
hnRNP A2/B1, Purα, and Sam68, are known to interact with FMR1 mRNA inclusions in vitro,
but unlike DGCR8, these interactions are not modified by CGG expansion1. Thus, it is unclear if
their sequestration contributes to disease pathogenesis.
A second potential mechanism of FXTAS pathogenesis is repeat-associated non-AUG
(RAN) translation. RAN translation occurs when repetitive mRNA sequences are translated
without an AUG initiation site. RAN translation can occur in all possible reading frames, which
can result in aberrant production of multiple repeat-containing proteins. In FXTAS, this process
involves a near-cognate ACG codon upstream of the CGG repeats in a short upstream open
reading frame (uORF) in the 5’ UTR of the FMR1 mRNA4. This codon causes leaky ribosomal
scanning that produces a polyglycine-containing protein called FMRpolyG (GGC) and a
polyalanine-containing protein, FMRpolyA (GCG)4. However, no RAN translation product is
detected in the CGG polyarginine frame18. Furthermore, the translation of the FMRpolyA
product is less efficient than the FMRpolyG product, leading researchers to postulate that
FMRpolyG is the main pathogenic driver through RAN translation in FXTAS18. Leaky
ribosomal scanning is a mechanism that occurs in the presence of an uORF in the 5’ UTR of
mRNA to ensure that translation is re-initiated at the main open reading frame (ORF), for FMRP
in this case4. If this did not occur, the FMRP ORF would not be initiated, and FMRP production
would not occur4. With that said, the ORFs of FMRpolyG and FMRP overlap by about 20 amino
acids, which could cause an interruption in translation re-initiation4. This may explain why the
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levels of FMRP can be decreased in pre-mutation carriers despite increased amounts of mRNA4.
It is also important to note that FMRpolyG has only been detected with CGG repeats above 60
and it co-localizes with ubiquitin-positive nuclear inclusions in FXTAS patient brain samples
(figure 2)4.

Figure 2. FMRpolyG and ubiquitin co-localization in FXTAS patient brain samples. Immunofluorescence of
post-mortem brain samples shows the presence of ubiquitin-positive inclusions (green) containing FMRpolyG (red)
co-localized in the nucleus of FXTAS neurons. This shows that the mutant protein FMRpolyG forms inclusions
inside of the nucleus and that they can co-localize with the inclusions previously noted in FXTAS neuropathology.
Adapted from4.

Association studies with FMRpolyG revealed that it interacts with lamina-associated
polypeptide 2-beta (LAP2), an isoform of the LAP2 protein that is anchored to the nuclear
membrane4. Lap2 assists in maintaining the inner nuclear membrane organization through
interactions with lamin B1 and lamin B2 proteins. In FXTAS patient brain, Lap2 and
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FMRpolyG are co-localized and lamin B1 is mis-localized, demonstrating that the organization
of the nuclear membrane is perturbed (figure 3). Disruption of the nuclear membrane often leads
to cell death, and overexpression of Lap2, which has no effect on control neurons, is sufficient
to rescue neurons expressing FMRpolyG4. Further study of these protein interactions could
reveal clues about FXTAS pathogenesis and could lead to potential therapeutic targets.

Figure 3. Immunofluorescence of FXTAS patient and control brain samples reveals disruption of nuclear
lamina. (Left) Co-localization of Lap2 (red) and FMRpolyG (green) in FXTAS patient brain samples. (Right)
lamin B1 (red) mis-localization to intranuclear inclusions containing FMRpolyG (green) in FXTAS patient brain
samples. In control brain samples, Lap2 and lamin B1 are localized to the nuclear membrane as they should be. In
the presence of FMRpolyG in FXTAS patient samples, Lap2 and lamin B1 co-localize with FMRpolyG-positive
inclusions. Adapted from4.

Induced pluripotent stem cells (iPSCs) can be differentiated into any cell type in the
body, making them a unique tool to model regional and tissue-specific effects of various
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disorders and provide a valuable method to study patient neurons19. However, reprogramming
adult cells, such as from a skin biopsy or blood sample, to iPSCs removes all markers of aging,
thus, returning cells to an embryonic-like state19,20. This in vitro method is appealing because it is
not subject to the same ethical considerations that are associated with embryonic stem cell
research, and allows for patient-specific research20. However, they are limited in the study of
adult onset diseases. In neurons differentiated from FXTAS patient-derived iPSCs, FMR1
mRNA levels are elevated up to three fold, which is consistent with the increased levels of the
FMR1 mRNA noted in FMR1 pre-mutation carriers4. Consistent with patient brain samples,
FMRpolyG inclusions and Lap2 are co-localized in FXTAS patient-derived neurons (figure 4),
which disrupts the normal localization of Lap24. In the presence of FMRpolyG inclusions,
lamin B1 is also mis-localized (figure 4)4.
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Figure 4. Immunocytochemistry of neurons differentiated from FXTAS patient-derived iPSCs reveals colocalization between FMRpolyG and Lap2 and a disruption of the nuclear membrane. (Left) Representative
images (top) and quantification (bottom) of co-localization of Lap2 (red) and FMRpolyG (green) in neurons
differentiated from FXTAS patient-derived iPSCs. (Right) Representative images (top) and quantification (bottom)
of mis-localization of lamin B1 (red) in the presence of FMRpolyG (green) intranuclear inclusions in FXTAS iPSCderived neurons. This shows that in the presence of FMRpolyG, the localization and organization of Lap2 and
lamin B1 are disrupted. Adapted from4.

One limitation in using iPSCs to model late-onset disorders, such as FXTAS, is that the
cells lose all age-related features during reprogramming, reverting back to an embryonic-like
state19. This is evidenced by longer telomeres, increased mitochondrial fitness, healthier nuclear
organization, decreased DNA damage, and decreased reactive oxygen species compared to adult
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donor cells prior to reprogramming19. This reversion to a developmental state confounds the
study of late onset phenotypes. Acceleration of aging via progerin treatment has been used to
overcome this19. Progerin is a truncated form of lamin A that causes Hutchinson Gilford Progeria
Syndrome (HGPS), a disease of premature aging19. Progerin is not only produced in HGPS, but
is produced at low levels in healthy individuals, as well19,21. Progerin production increases over
time in the absence of a mutation, suggesting a role in normal aging21. The Lamin A protein is
involved in organization of the nuclear membrane and progerin disrupts the normal
organization19. This disorganization perturbs nuclear processes, including mRNA production, the
DNA damage response, and the cell cycle19. Progerin treatment is able to induce cellular aging in
neurons differentiated from iPSCs, restoring markers of natural aging19. Progerin ‘aged’ neurons
display increased nuclear blebbing, DNA damage, protein aggregation, and reactive oxygen
species, decreased dendrite length, and changes in the cell cycle and chromatin modification
processes, demonstrating advanced biological age (figure 5)19.
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Figure 5. Progerin treatment reveals phenotypes of aging in young and old donor midbrain dopaminergic
(mDA) neurons differentiated from iPSCs. (Top Left) Compared to nuclear GFP control, progerin treatment
increases nuclear blebbing (Lamin B2) and DNA damage (H2AX) in iPSC-derived neurons, both age-like
phenotypes. (Top Right) Progerin treatment induces reactive oxygen species in iPSC-derived neurons from young
and old donors, another age-like phenotype. (Bottom) Progerin treatment reduces dendrite length (MAP2) in iPSCderived mDA neurons from both young and old donors. Adapted from19.
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Using progerin, we are investigating whether there is a link between neuronal aging and
FXTAS pathogenesis. If progerin-induced aging of FXTAS patient iPSC-derived neurons reveals
greater disease-specific pathology, it would suggest that aging is directly involved in FXTAS
pathogenesis and provide rationale for the study of anti-aging therapies on FXTAS onset and
progression.
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CHAPTER II: RESULTS
Progerin Treatment Causes Increased Nuclear Blebbing
Neurons transduced with AAV-progerin-GFP displayed increased nuclear blebbing, a
sign of dysfunction in the nuclear scaffolding. Compared to neurons transduced with AAVnuclear-GFP (nGFP), neurons treated with progerin showed a 19% increase in nuclear blebbing
(figure 6B). This nuclear abnormality is seen in cells during aging. Since the cells treated with
progerin showed this increased abnormal nuclear morphology, we can conclude that the progerin
was successful in aging the neurons. While some cells treated with the nGFP displayed nuclear
abnormalities, it was not as dramatic as those treated with progerin. Figure 6A shows the
differences between a cell with nuclear blebbing compared to one without.

A
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Figure 6. A comparison of the amount of nuclear abnormality displayed in neurons treated with progerin and
the control. A) Immunocytochemistry revealing the differences between a normal and an abnormal nucleus (nuclear
blebbing/folding). Cells were labeled using DAPI (nucleus) and GFP (AAV-progerin-GFP or AAV-nGFP). B)
Quantification of the amount of nuclear blebbing between neurons treated with progerin and neurons treated with
the control.

Some Neurons Reveal Co-Localization Between FMRpolyG and Lap2

Following a study that showed the co-localization of Lap2 with FMRpolyG in
telencephalic FXTAS neurons, we expected our FXTAS neurons to display this co-localization.
Our lab wanted to investigate whether aging neurons with progerin would increase the amount of
FMRpolyG inclusions, and if those inclusions would co-localize with Lap2. Comparing
neurons treated with AAV-progerin-GFP and AAV-nGFP, there was no significant difference
noted in the number of cells with FMRpolyG and Lap2 co-localization (Figure 7). It was also
expected that the inclusions would form in the nucleus, as established in previous studies. Of the
neurons in our study that showed the protein co-localization, a majority of the proteins were in
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the cytoplasm of the cell (Figure 7). It is possible that the nuclei of these cells had increased
permeability from transducing them with a nuclear protein, which could cause the protein
aggregates to leave the nucleus. Nonetheless, the FMRpolyG found in these cells did mislocalize the Lap2 from the nuclear membrane, which can lead to cellular dysfunction.
It was expected that the neurons treated with the AAV-nGFP would display less colocalization between FMRpolyG and Lap2, as we hypothesized that this process would increase
in aged cells. Our results only include one cell treated with the control virus and stained for
FMRpolyG and Lap2, of which co-localization was noted. Because of the small sample size,
we cannot conclude that there was a difference between the two viral conditions in this set of
immunocytochemistry (ICC). Further analysis of the co-localization between FMRpolyG and
Lap2 in greater numbers of neurons treated with either progerin or the control is needed before
a conclusion can be formed.

Figure 7. A comparison of the amount of co-localization between FMRpolyG and Lap2 in neurons treated
with either AAV-progerin-GFP or AAV-nGFP. Immunocytochemistry reveals co-localization between
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FMRpolyG (red) and Lap2 (magenta) in neurons treated with AAV-progerin-GFP, both inside and outside of the
nucleus (top). Of the one neuron gathered for analysis that was treated with AAV-nGFP, FMRpolyG and Lap2
display co-localization outside of the nucleus (bottom).

Figure 8 shows an example of the presence of FMRpolyG and Lap2 co-localizing
outside of the nucleus. This was not expected because Lap2 is a nuclear membrane scaffolding
protein, therefore it is expected that inclusions would form inside the nucleus. While this was not
expected, the cells are still showing that the presence of FMRpolyG can possibly disrupt the
nuclear membrane by interfering with the localization of Lap2.

Figure 8. Co-localization of FMRpolyG and Lap2 outside of the nucleus. The presence of FMRpolyG
aggregates (red) in the cytoplasm of the cell co-localize with Lap2 (magenta) in a large proportion of our FXTAS
neurons.

Progerin May Co-localize with FMRpolyG in Some Cells
Some neurons from each of the FXTAS cell lines displayed co-localization between
FMRpolyG, Lap2, and progerin (figure 9). This co-localization was not present in cells treated
with the nGFP control. This is not entirely surprising, as progerin is a truncated form of the
lamin A protein, which is another scaffolding protein of the nuclear membrane. Progerin is
16

known to localize to the nuclear membrane, whereas the nuclear-GFP control should be diffuse
throughout the nucleus. Since Lap2 mis-localizes from the nuclear membrane in the presence of
FMRpolyG in some cases, it is plausible that the progerin protein could also mis-localize. This
co-localization was noted in about one-third of the neurons showing a co-localization between
FMRpolyG and Lap2.

Figure 9. Some FXTAS neurons display co-localization between FMRpolyG, Lap2, and progerin. In neurons
treated with AAV-progerin-GFP, some cells showed a co-localization between FMRpolyG (red), Lap2 (magenta),
and progerin (green); this co-localization disrupts the nuclear membrane structure as seen in the photos above.

Some Neurons May Have Increased Nuclear Permeability
Both the AAV-progerin-GFP and the AAV-nGFP should produce protein that
specifically labels the nucleus. The progerin-GFP typically localizes to the nuclear membrane,
whereas the nuclear-GFP is typically diffuse within the nucleus. About 70% of cells transduced
with nGFP had GFP staining throughout the cell, compared to about 20% of progerin-treated
cells that had this filling outside of the nucleus (figure 10B). It could be possible that this signal
was produced from background fluorescence or non-specific binding of the antibody. It is also
possible that the cells transduced with nGFP have greater nuclear permeability from using a
diffuse nuclear protein. This could explain why the GFP signal was diffuse throughout many of
the cells. Figure 10A shows a representative image of the GFP cell filling.
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Figure 10. GFP signal outside of the nucleus was recorded in greater than 70% of the transduced nGFP
neurons. In neurons treated with AAV-nGFP, many of the cells had GFP (green) diffuse throughout the cell when
the GFP protein should have been in the nucleus. Some of the cells transduced with AAV-progerin-GFP had this cell
filling, but the percentage was much lower.

Cleaved Caspase 3 Was Comparable in Progerin and Control-Treated Neurons
Cleaved caspase 3 is a marker of apoptosis. This marker is present in dying cells, so it is
expected that cells treated with progerin will have a greater amount of cleaved caspase 3 in the
cytoplasm compared to cells treated with the control. In comparing FXTAS neurons treated with
AAV-progerin-GFP and AAV-nGFP, the levels of cleaved caspase 3 were similar (figure 11B).
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The presence of this apoptotic marker was seen in less than half of the cells in both conditions,
indicating that the levels of cell death were not significantly high. This was not expected, as the
aging caused by progerin was hypothesized to cause greater dysfunction in FXTAS cells
compared to “young” cells. Interestingly, the number of cells containing cleaved caspase 3 was
greater in neurons treated with the nGFP control. Figure 11A is a representative image of the
cleaved caspase 3 signal in FXTAS neurons.
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B
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Figure 11. A comparison of the level of apoptosis in neurons treated with either AAV-progerin-GFP or AAVnGFP. A) Immunocytochemistry showing a representative image of the presence of cleaved caspase 3 (magenta) in
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FXTAS neurons treated with either progerin or control. B) Quantification of the percentage of cells with a cleaved
caspase 3 signal between FXTAS neurons treated with progerin or control. The levels of cleaved caspase 3 were
similar between treatments, indicating that apoptosis was not increased in either condition.

Progerin-Treated Neurons Display Increased DNA Damage
DNA damage is another marker of aging in cells. DNA is the backbone of all cellular
processes; therefore, it is necessary for cell viability. In neurons treated with AAV-progerinGFP, the presence of DNA damage was increased compared to neurons treated with AAV-nGFP
(figure 12). Interestingly, a large majority of the neurons treated with AAV-nGFP showed the
signal for DNA damage staining throughout the cytoplasm (figure 12). This signal could be due
to bleed through from other color channels or may represent a leaky nucleus. The latter is
unlikely, though, as DNA is a large charged biomolecule unlikely to pass through even a very
disrupted membrane, and if this were to happen, DAPI would also be expected to stain the whole
cell. This is because DAPI binds to specific bases in the DNA, all of which would be present in
the cytoplasm of these cells. Because of the strange signal in cells treated with AAV-nGFP, it is
difficult to conclude a definitive difference between the levels of DNA damage in each
condition.
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Figure 12. A comparison between the presence of a DNA damage signal inside of the nucleus and outside of
the nucleus. A small percentage of neurons treated with AAV-progerin-GFP (green) showed DNA damage (15A3,
red), characterized by foci inside of the nucleus. A large percentage of neurons treated with AAV-nGFP (green)
showed DNA (15A3, red) damage signal outside of the nucleus, often diffuse throughout the cell.

Abnormal Morphology Observed in Progerin and Control-Treated Neurons
FXTAS neurons were stained for MAP2 and Beta-III Tubulin to assess general health
and complexity. Figure 13 shows representative images of the neurons. The shapes of the
neurons from each treatment are similar, and the number of dead cells per condition were
insignificant. Overall, the neurons of both treatment groups displayed complex and abnormal
morphology. The cells did not have normal neuronal shapes, but the MAP2 staining confirms
that they are neurons, as MAP2 is a neuron-specific protein. The abnormal morphology is most
likely due to the low density of cells, allowing them to grow unhindered by other cells. We were
unable to conclude anything about general neuronal health and complexity due to the abnormal
morphologies.
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Figure 13. Both neurons treated with AAV-progerin-GFP and AAV-nGFP showed abnormal morphology.
Dendritic complexity was visualized using MAP2 (red) and general neuronal health was visualized using Beta III
Tubulin (magenta). While these cells do not resemble normal neuronal morphology, staining with MAP2 confirms
that they are neurons.

FXTAS Neurons Are Difficult to Dissociate for Sorting
Cell sorting is useful in studies such as this, as analysis of only GFP-positive cells is
desired. The ability to sort cells into different populations based on size, complexity, and
fluorescence would be useful for Western blot analysis of FMRpolyG in only progerin and
control-treated cells. In an attempt to separate individual neurons in this study, a dissociation
protocol was used. The cells were then run through a flow cytometer to analyze each sample for
different population. The size and complexity of the components of the sample were measured
along with the fluorescent intensity of GFP. Unfortunately, no single populations were recorded
in the analysis. Figure 14 shows a graph comparing size and complexity, as well as complexity
and fluorescence intensity. It is not possible to discern any different components from the mass
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of signal that was recorded. The fluorescent signal was high, indicating that viral transduction
could have been successful in the neurons. The components of the sample with low size and
complexity are likely various cellular debris. The larger components with greater complexity
could be clumps of neurons present in the sample, which would indicate that the dissociation
protocol was not able to break the neuronal connections. In the future, our lab is going to
determine where GFP alone falls on the graph to determine if any of the “debris” is GFP. This
could give us insight into whether the dissociation protocol was simply too harsh on the cells and
caused them to lyse and spill their contents. Further investigation is required to troubleshoot this
protocol for the use in future cell sorting procedures.

A

B

Figure 14. Flow cytometry analysis to test cell dissociation protocol. A) This graph is comparing the size to the
complexity of the components of the sample of neurons. No single population is detected, indicating that a single
cell suspension was not achieved B) This graph is comparing the fluorescence intensity to the complexity of the
components of the sample. The signal of GFP is high in this case.
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CHAPTER III: DISCUSSION
The viral transduction of AAV-progerin-GFP and AAV-nGFP was successful in that
about a 40% transduction rate was achieved. On the contrary, the number of total cells used in
this study was insufficient to answer many of the questions that were originally proposed. In
FXTAS neurons treated with AAV-progerin-GFP, there was a significant increase in nuclear
morphological changes and an increase in DNA damage compared to neurons treated with AAVnGFP. There was no significant increase in the number of apoptotic cells, and it was not able to
be determined if cells treated with progerin displayed increased co-localization between
FMRpolyG and Lap2.
One conclusion of this study is that the cells treated with progerin were aged to some
degree compared to the cells treated with the control. The presence of nuclear blebbing is a sign
of nuclear dysfunction, which often leads to cell dysfunction and death. The number of cells with
nuclear blebbing was increased by about 20% in cells treated with progerin, which confirms that
the nuclear integrity of these cells was compromised more than those treated with the control.
While this isn’t a definitive quantification of aging itself, it is one sign of aging in neurons.
FMRpolyG and Lap2 were co-localized in FXTAS neurons treated with progerin, but
the localization of these proteins in the cytoplasm was not expected. It is unclear whether this
was from over permeabilization of the cells, but further investigation into the relationship
between FMRpolyG and Lap2 is still required. The neuron treated with the nuclear-GFP control
also showed co-localization between these two proteins. A conclusion cannot be made regarding
whether progerin and control-treated neurons display differing levels of co-localization between
these two proteins because the sample size of both conditions are too low. One interesting note is
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of the co-localization between FMRpolyG inclusions and progerin in this study. Since
FMRpolyG seems to disrupt proteins of the nuclear membrane, it is possible that it can also colocalize with progerin, a shortened form of the lamin A protein. Again, the sample size is too
small to draw any conclusions, but the progerin co-localization question is a future aspect to
study further.
The diffuse signal of the DNA damage antibody and GFP in some cells is another
interesting question that needs further analysis. It is possible that the nuclei of these cells are
highly permeable, leaking their contents into the cytoplasm. It is also possible that the antibody
signals are from bleed through from other colors in the sample. Another trial with a larger
sample is needed to study this more.
For future protein analysis using a Western blot, it is important to optimize the
dissociation protocol for neuronal cultures. Neurons are tricky to dissociate because they form
complex connections between one another. In the next dissociation trial, our lab is planning to
perform extra mechanical steps to aid the dissociation of the clumps of cells to a single cell
suspension. If the protocol is optimized for sorting cells into a population of single cells, the
samples could be sorted by GFP fluorescence. This would ensure that only GFP-positive cells
are used in a Western blot, giving a more accurate comparison of the FMRpolyG levels in
progerin and control-treated cells.
The biggest limitation of this study was that a control cell line was not available for use
in the analysis. This study will be repeated and will include two cell lines that do not have
expanded CGG tract lengths to compare to the two FXTAS lines. Adding data from AAVprogerin-GFP and AAV-nGFP treated control lines will hopefully give us a greater
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understanding of the co-localization speculations and of the effect of aging on FXTAS
pathogenesis.
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CHAPTER IV: METHODOLOGY

Experimental Conditions
There are a total of six conditions for this study. Two FXTAS and one control NSC lines
were treated with adeno-associated virus (AAV)-progerin-GFP or AAV-nuclear GFP (nGFP)
control. Immunocytochemistry (ICC) was performed.

Neural Stem Cell Culture
FXTAS neural stem cells (NSCs) (Generous gift, Dr. Nicolas Charlet-Berguerand) and
control NSCs (Generous gift, Dr. Virginia Mattis) were expanded in suspension as neurospheres.
Tissue culture flasks were used with no cell matrix treatment. The cells were expanded in NSC
Maintenance Media: DMEM/F-12 (STEMCELL Technologies) supplemented with 1X SM1
(STEMCELL Technologies), 0.2 ng/mL Human Recombinant Epidermal Growth Factor
(rhEGF) (Fisher Scientific), 2.0 ng/mL Human Recombinant Fibroblast Growth Factor (rhFGF)
(STEMCELL Technologies), 0.5 U/mL Heparin (Millipore Sigma), 1X Penicillin/Streptomycin).
The media was changed when a color change close to yellow was noted. Once the spheres
reached about 1mm in size, they were manually passaged by placing the neurospheres in a petri
dish with little media and using a sterile blade to chop them. They were incubated at 37°C and
5% CO2 for the duration of expansion.
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Neuronal Differentiation
The neurospheres in suspension were collected and passed through an 18-gague needle
attached to a syringe four times to break up the spheres. The cells were centrifuged at 1,000
RPM for 4 minutes. Following centrifugation, the supernatant was removed, and the pellet was
resuspended in 12mL NSC maintenance media for plating a total of 24 wells of a 24 well plate.
The media and pellet were pipetted 15 times using a 10mL serological pipette in order to
homogenize the mixture. The cells were seeded onto coverslips (for ICC) and regular wells (for
Western blot) coated in poly-L-lysine and matrigel21. The media and cell mixture were evenly
distributed between all of the wells for each line, 0.5 mL per well. The plates were left in an
incubator at 37°C and 5% CO2 overnight and checked the next day for survival. Another 0.5 mL
of NSC maintenance media was added to the wells the next day. On day 5, half of the media was
removed and replaced with BrainPhys Neuronal Differentiation Media (STEMCELL
Technologies): BrainPhys basal media, 20 L/mL SM1 (STEMCELL Technologies), 10 L/mL
N2 Supplement-A (STEMCELL Technologies), 20 ng/mL Human Recombinant Brain-Derived
Neurotrophic Factor (rhBDNF) (STEMCELL Technologies), 20 ng/mL Human Recombinant
Glial-Derived Neurotrophic Factor (rhGDNF) (STEMCELL Technologies), 1mM DibutyrylcAMP (STEMCELL Technologies), and 200 nM ascorbic acid (Fisher Scientific). A half-media
change was performed every 2-3 days for 21 days for the neurons to reached maturity.
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Viral Transduction
The progerin-GFP and nuclear GFP control were delivered to the cells using an adenoassociated virus. The virus was delivered on day 21 of neuronal differentiation and the cells were
collected 9 days later. Preliminary experiments determined that the virus takes 4 days to reach
full expression. Consistent with a study utilizing progerin-induced aging in Parkinson Disease
neurons, the progerin was expressed for an additional 5 days18.

Immunocytochemistry
The cells were fixed in 4% paraformaldehyde at room temperature for 30 minutes. After
3 5 min washes in PBS, the coverslips were incubated in blocking solution (1X PBS, 3% Bovine
Serum Albumin (BSA), 5% Normal Goat Serum (NGS), and 0.3% Triton-X100) at room
temperature for 30 minutes. The coverslips were incubated in the primary antibody solution at
4°C overnight. The primary antibody solution is the blocking solution containing the primary
antibodies (see antibodies and dilutions below) Three more wash steps were performed using 1X
PBS, each for 5 minutes. The coverslips were incubated in the secondary antibody solution
(blocking solution with the secondary antibodies, see below) at room temperature for 2 hours,
ensuring the samples were in complete darkness to protect the light-sensitive fluorophores. Three
wash steps were performed using 1X PBS, each for 5 minutes. The coverslips were removed
from the plates and transferred to a slide in groups of 3. The slide contained drops of ProLong®
Gold Antifade mounting media containing DAPI (Thermo Fisher P36931) and coverslips were
placed face-down. Visualization was done using a Zeiss LSM 710 confocal microscope and the
ZEN imaging software. Analysis was done using ImageJ software.
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Three sets of ICC were performed. The first set included antibodies for MAP2 (1:50,
Invitrogen PA5-17646) and Beta III tubulin (1:300, Abcam ab131205) to investigate dendritic
complexity and neuronal health. The second set was stained for DNA damage (15A3, 1:500,
Abcam ab62623) and cleaved caspase 3 (1:400, Cell Signaling 9664) to investigate DNA
damage and apoptosis. Greater than 3 foci were used as a benchmark to determine the presence
of DNA damage. The final set was stained for FMRpolyG (1:100, Generous gift, Nicolas
Charlet-Berguerand) and Lap2 (1:200, Millipore Sigma 06-1002) to investigate FXTAS
pathology and nuclear lamina integrity. All three sets were also stained for GFP (1:2000, Abcam
ab13970) to reveal progerin-GFP or nuclear-GFP control.

Flow Cytometry
One well of each of the two FXTAS lines treated with either progerin or the control were
dissociated and run on a flow cytometer (BD Biosciences Accuri C6 Plus) to determine if
separation of the neuronal network was possible. The dissociation solution (Dulbecco’s
Phosphate Buffered Solution, 2% BSA, 25 mM HEPES, 5 mM MgCl2, 0.2 mg/mL DNase 1) was
added to each well. A large pipette tip was used to scrape the wells into 400µL of the solution
and were collected into a 5mL snap cap tube. A 200µL wash was performed to collect any
remaining cells. The cells in each tube were then passed through a 22-gague needle 10 times to
aid the dissociation. Each sample was passed through the flow cytometer to determine if a
population of single cells was present using GFP fluorescent signal. This trial was performed to
determine if this protocol could be used in Fluorescence Activated Cell Sorting (FACS) to
separate GFP-positive cells for use in a Western blot.
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